Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter

Investor News

Clinical Development News
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
Approvable Letters
Approval and Marketing Clearance
Recalls and Warnings

Deals & Dollars News
Earnings Reports
Mergers and Acquisitions

IPO News

Clinical - Phase III
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain 9/30/2014 11:07:53 AM
TherapeuticsMD, Inc.  (TXMD) Begins Phase 3 Clinical Trial Of TX-004HR (VagiCapTM) For The Treatment Of Painful Intercourse, A Symptom Of VVA, Due To Menopause 9/30/2014 9:58:33 AM
Novartis AG (NVS) Drug Afinitor Is First Treatment For Advanced Pancreatic NET To Provide Overall Survival Of More Than 3.5 Years In Phase 3 Trial 9/29/2014 7:44:09 AM
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014 6:36:12 AM
Seattle Genetics, Inc. (SGEN) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Announce Positive Data From Phase 3 AETHERA Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) For Consolidation In Post-Transplant Hodgkin Lymphoma 9/29/2014 11:39:13 AM
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast On September 29, 2014 Regarding Top-Line Data From ADCETRIS® (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 9/29/2014 11:41:50 AM
Genentech (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014 11:56:51 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 9/29/2014 1:12:57 PM
Bristol-Myers Squibb Company (BMY) Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor 9/29/2014 11:55:22 AM
Provectus Biopharmaceuticals Inc. Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10 9/29/2014 11:43:12 AM
Roche (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf® (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014 11:17:47 AM
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014 9:02:17 AM
Roche (RHHBY)’s Perjeta Regimen Extended The Lives Of People With An Aggressive Type Of Metastatic Breast Cancer By 15.7 Months Compared To Herceptin And Chemotherapy 9/29/2014 10:18:33 AM
Exelixis, Inc. (EXEL) Announces Positive Results From Phase 3 Pivotal Trial Of Cobimetinib In Combination With Vemurafenib In Patients With BRAF V600 Mutation-Positive Advanced Melanoma 9/29/2014 10:02:23 AM
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014 9:38:10 AM